Physician profile
Michael Gore
NPI 1003823378
$1,045.93
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $938 · 2022: $46.97 · 2023: $29.30 · 2024: $31.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $60.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $60.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $231.21 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.33 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $83.82 | 2021 | |
| Indivior INC. | $80.43 | 2021 | |
| Biodelivery Sciences International, INC. | $70.17 | 2021 | |
| Pfizer INC. | $67.33 | 2021 | |
| Scilex Pharmaceuticals INC. | $56.46 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $45.70 | 2021 | |
| Collegium Pharmaceutical, INC. | $37.65 | 2021 | |
| Currax Pharmaceuticals LLC | $34.13 | 2021 | |
| Hikma Pharmaceuticals USA | $29.71 | 2021 | |
| Lundbeck LLC | $22.85 | 2021 | |
| Almatica Pharma LLC | $22.06 | 2021 | |
| Allergan, INC. | $16.40 | 2021 | |
| Lilly USA, LLC | $15.54 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $15.19 | 2021 | |
| Redhill Biopharma INC. | $12.42 | 2021 | |
| Forte Bio-Pharma LLC | $8.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.